News Sentiment

UPB sentiment intelligence

Upstream Bio, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.01 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-6.9% over one week, +12.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

ETFs Investing in Upstream Bio, Inc. Stocks

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -6.9% Price reacting lower
Trend fit Trend inactive 12.2% over four weeks
Fair value -53.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 27
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 6
GlobeNewswire 4
simplywall.st 4
Stock Titan 3
Moomoo 3
TradingKey 3
MSN 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 13
Analyst action 8
Guidance 2
Balance sheet 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
TradingView Direct company coverage

ETFs Investing in Upstream Bio, Inc. Stocks

This article lists various ETFs that hold shares of Upstream Bio, Inc. (UPB), providing details such as market value, weight in the ETF, issuer, management style, expense ratio, AUM, price, and performance metrics. The information aims to help investors identify funds that offer

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 18:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Upstream Bio, Inc. – NASDAQ:UPB

This article provides the "Price to earnings forward" metric for Upstream Bio, Inc. (NASDAQ: UPB) as listed on TradingView. It indicates that the market was closed with no trades recorded at the time of data retrieval. The report presents the value and percentage change for this

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 09:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Upstream Bio, Inc. – NASDAQ:UPB

This article provides the "Price to book forward" value for Upstream Bio, Inc. (NASDAQ: UPB). It includes basic financial information and indicates that the market was closed with no trades at the time of publication. The data is presented within the context of a financial market

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 13:42
Source
TradingView
Finviz Direct company coverage

UPB - Upstream Bio Inc Dividends

This article provides detailed financial data and performance metrics for Upstream Bio Inc. (UPB). It lists various financial ratios, stock performance over different periods, insider and institutional ownership, and analyst recommendations, noting that the company does not curre

Tone
Negative 40/100
Event
Analyst action
Published
06 Jul 2026 04:39
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Upstream Bio, Inc. – NASDAQ:UPB

The article focuses on the "Price to sales forward" metric for Upstream Bio, Inc. (NASDAQ: UPB). It provides a snapshot of the company's financial data on TradingView, indicating that the market was closed at the time of viewing. The content is primarily a data point with no furt

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 09:40
Source
TradingView
Stock Titan Direct company coverage

If You Invested $1,000 in UpStream Bio Inc. (UPB)

This article examines the historical performance of a $1,000 investment in UpStream Bio Inc. (UPB), a clinical-stage biotechnology company focused on inflammatory diseases. It provides detailed information on UPB's core drug candidate, verekitug, its mechanism of action, and its

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 05:11
Source
Stock Titan
Moomoo Direct company coverage

Here's Why We're Watching Upstream Bio's (NASDAQ:UPB) Cash Burn Situation

This article examines Upstream Bio's cash burn rate and its implications for the company's future operations. It analyzes the current cash reserves against the burn rate to estimate how long the company can continue funding its activities without additional capital. The article h

Tone
Negative 28/100
Event
Balance sheet
Published
02 Jul 2026 14:41
Source
Moomoo
TradingView Direct company coverage

Enterprise value to EBIT forward of Upstream Bio, Inc. – NASDAQ:UPB

The article focuses on the enterprise value to EBIT forward ratio for Upstream Bio, Inc., trading under the NASDAQ symbol UPB. It appears to be a financial data point presented within a trading platform context, with placeholders for actual financial figures.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 17:40
Source
TradingView
TradingView Direct company coverage

Upstream Bio, Inc. Actuals & Estimates (NASDAQ:UPB)

This article provides an overview of Upstream Bio, Inc. (NASDAQ: UPB) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details key financial actuals and estimates such as earnings per share and revenue, indicating t

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 19:09
Source
TradingView
MSN Direct company coverage

Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates

Upstream Bio, Inc. (UPB) reported a Q1 loss per share of $0.93, which was lower than the analyst estimate of a $1.09 loss per share. The company also announced Q1 revenue of $180,000, surpassing the analyst consensus estimate of $170,000.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 11:09
Source
MSN
Insider Monkey Direct company coverage

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

Upstream Bio, Inc. (NASDAQ:UPB) is highlighted as a promising small-cap stock following new analyst coverage from H.C. Wainwright, which initiated a Buy rating and a $36 price target. The analyst praised the company's lead candidate, verekitug, an antibody targeting the thymic st

Tone
Positive 70/100
Event
Analyst action
Published
25 Jun 2026 08:42
Source
Insider Monkey
TradingKey Direct company coverage

Upstream Bio Inc (UPB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Upstream Bio Inc (UPB), covering its current price momentum, support and resistance levels, and various technical indicators and moving averages. According to the analysis, UPB's price momentum score is 6.46, and it's trading between

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 01:40
Source
TradingKey
TradingKey Direct company coverage

Upstream Bio Inc (UPB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Upstream Bio Inc's (UPB) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no data for past stock splits. The page includes current stock price information, marke

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:39
Source
TradingKey
TradingKey Direct company coverage

Upstream Bio Inc (UPB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Upstream Bio Inc (UPB), noting its current valuation score is 8.14, ranking 168 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -2.04 and states that relevant data for P/B

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 04:10
Source
TradingKey
Quiver Quantitative Direct company coverage

Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms

Upstream Bio announced positive Phase 2 results for its drug verekitug in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The trial demonstrated significant improvements in nasal polyp scores and key secondary endpoints like nasal congestion and total symptom scores,

Tone
Positive 70/100
Event
Earnings
Published
14 Jun 2026 14:10
Source
Quiver Quantitative
GlobeNewswire Direct company coverage

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

Upstream Bio presented new responder analyses from its Phase 2 VIBRANT trial for verekitug, showing clinically meaningful improvements in chronic rhinosinusitis with nasal polyps (CRSwNP). The data indicated that approximately 80% of participants treated with verekitug every thre

Tone
Positive 74/100
Event
Market update
Published
14 Jun 2026 14:09
Source
GlobeNewswire
Stock Titan Direct company coverage

Quarterly nasal polyp treatment improved symptoms for most trial patients

Upstream Bio presented new analyses from its Phase 2 VIBRANT trial for verekitug, showing clinically meaningful improvements in chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms for a significant majority of patients with quarterly dosing. Approximately 80% achieved impr

Tone
Positive 71/100
Event
Market update
Published
14 Jun 2026 14:09
Source
Stock Titan
Moomoo Direct company coverage

Upstream Bio Cut to Neutral From Overweight by JP Morgan

JP Morgan has downgraded Upstream Bio's rating from Overweight to Neutral. This change in rating suggests a revised outlook on the company's stock performance by the investment bank.

Tone
Negative 32/100
Event
Guidance
Published
13 Jun 2026 12:10
Source
Moomoo
marketscreener.com Direct company coverage

JPMorgan Downgrades Upstream Bio to Neutral From Overweight, Cuts Price Target to $8 From $35

JPMorgan downgraded Upstream Bio (UPB) from Overweight to Neutral and significantly cut its price target from $35 to $8. This adjustment reflects a revised outlook from the investment bank regarding the biotechnology company. Upstream Bio is a clinical-stage biotechnology company

Tone
Negative 9/100
Event
Analyst action
Published
12 Jun 2026 11:09
Source
marketscreener.com
Moomoo Direct company coverage

J.P. Morgan Downgrades UpStream Bio(UPB.US) to Hold Rating, Announces Target Price $8

J.P. Morgan has downgraded UpStream Bio (UPB.US) from an Overweight to a Hold rating. The firm also announced a new target price of $8 for the company's stock. This change in rating reflects J.P. Morgan's updated outlook on UpStream Bio's financial performance and market potentia

Tone
Negative 29/100
Event
Analyst action
Published
12 Jun 2026 10:09
Source
Moomoo
The Globe and Mail Direct company coverage

Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor

Upstream Bio, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected two Class II directors, H. Edward Fleming, Jr., M.D., and Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A., to serve until the 2029 annual meeting. Investors also ratified PricewaterhouseCoopers L

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 16:10
Source
The Globe and Mail
GlobeNewswire Direct company coverage

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio announced that additional efficacy data from its Phase 2 VIBRANT trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congres

Tone
Positive 72/100
Event
Market update
Published
08 Jun 2026 22:08
Source
GlobeNewswire
Stock Titan Direct company coverage

Nasal polyp drug Verekitug Phase 2 data to be aired at EAACI 2026

Upstream Bio (NASDAQ: UPB) will present additional efficacy data from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI 2026 Congress on June 14, 2026. The presentation will feature a responder analysis highlighting clinical

Tone
Positive 70/100
Event
Market update
Published
08 Jun 2026 10:39
Source
Stock Titan
MSN Direct company coverage

Upstream Bio (UPB) price target decreased by 18.03% to 51.00

Upstream Bio's price target has been decreased by 18.03% to $51.00. This adjustment indicates a notable change in the financial outlook for the company.

Tone
Negative 14/100
Event
Guidance
Published
04 Jun 2026 20:10
Source
MSN